Pesquisas alternativas:
completely phased » completely healed (Expandir a Pesquisa), completed phase (Expandir a Pesquisa), completely revised (Expandir a Pesquisa)
daily completely » cavity completely (Expandir a Pesquisa), weakly completely (Expandir a Pesquisa), aids completely (Expandir a Pesquisa)
phased non » phase non (Expandir a Pesquisa), phased long (Expandir a Pesquisa), based non (Expandir a Pesquisa)
nacl comer » nacl complex (Expandir a Pesquisa)
comps con » compost con (Expandir a Pesquisa), comps los (Expandir a Pesquisa)
comer dan » romer dan (Expandir a Pesquisa), comer diane (Expandir a Pesquisa), comer vann (Expandir a Pesquisa)
3.5 nacl » 0.9 nacl (Expandir a Pesquisa), 3 nacl (Expandir a Pesquisa)
l comps » m comps (Expandir a Pesquisa)
con net » con nee (Expandir a Pesquisa), non net (Expandir a Pesquisa), con note (Expandir a Pesquisa)
a daily » _ daily (Expandir a Pesquisa)
dan non » than non (Expandir a Pesquisa), dan ning (Expandir a Pesquisa)
completely phased » completely healed (Expandir a Pesquisa), completed phase (Expandir a Pesquisa), completely revised (Expandir a Pesquisa)
daily completely » cavity completely (Expandir a Pesquisa), weakly completely (Expandir a Pesquisa), aids completely (Expandir a Pesquisa)
phased non » phase non (Expandir a Pesquisa), phased long (Expandir a Pesquisa), based non (Expandir a Pesquisa)
nacl comer » nacl complex (Expandir a Pesquisa)
comps con » compost con (Expandir a Pesquisa), comps los (Expandir a Pesquisa)
comer dan » romer dan (Expandir a Pesquisa), comer diane (Expandir a Pesquisa), comer vann (Expandir a Pesquisa)
3.5 nacl » 0.9 nacl (Expandir a Pesquisa), 3 nacl (Expandir a Pesquisa)
l comps » m comps (Expandir a Pesquisa)
con net » con nee (Expandir a Pesquisa), non net (Expandir a Pesquisa), con note (Expandir a Pesquisa)
a daily » _ daily (Expandir a Pesquisa)
dan non » than non (Expandir a Pesquisa), dan ning (Expandir a Pesquisa)
41
Por Schild, Steven E., Hillman, Shauna L., Tan, Angelina D., Ross, Helen J., McGinnis, William L., Garces, Yolanda A., Graham, David L., Adjei, Alex A., Jett, James R.
Publicado no J Thorac Oncol (2017)
“... and 5 had stages I-II disease. RESULTS: Patients were followed until death or for a minimum of 5 years...”Publicado no J Thorac Oncol (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
42
Por Boland, Patrick M, Meyer, Joshua E, Berger, Adam C, Cohen, Steven J, Neuman, Tzahi, Cooper, Harry S, Olszanski, Anthony J, Davey, Monica, Cheng, Jonathan D, Lebenthal, Abraham, Burtness, Barbara A, Scott, Walter J, Astsaturov, Igor A
Publicado no Am J Clin Oncol (2017)
“... without prior therapy were enrolled in a 3+3 phase 1 design. Patients received once daily vandetanib...”Publicado no Am J Clin Oncol (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
43
Por Dassen, Anneriet E, Bernards, Nienke, Lemmens, Valery E P P, van de Wouw, Yes A J, Bosscha, Koop, Creemers, Geert-Jan, Pruijt, Hans J F M
Publicado no World J Gastrointest Surg (2016)
“..., four developed metastatic disease and 76.5% received a curative resection. In 3 patients a pCR was seen...”Publicado no World J Gastrointest Surg (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
44
Por Pili, Roberto, Liu, Glenn, Chintala, Sreenivasulu, Verheul, Hendrick, Rehman, Shabnam, Attwood, Kristopher, Lodge, Martin A, Wahl, Richard, Martin, James I, Miles, Kiersten Marie, Paesante, Silvia, Adelaiye, Remi, Godoy, Alejandro, King, Serina, Zwiebel, James, Carducci, Michael A
Publicado no Br J Cancer (2017)
“... of vorinostat 200 mg orally two times daily × 2 weeks, and bevacizumab 15 mg kg(−1) intravenously every 3 weeks...”Publicado no Br J Cancer (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
45
“... to continue using FES beyond that phase. Average daily use was 5.6 hours (SD 2.3). Improved dorsiflexion...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
46
Por Gopal, Ajay K., Press, Oliver W., Shustov, Andrei R., Petersdorf, Stephen H., Gooley, Ted A., Daniels, Jasmine T., Garrison, Mitchell A., Gjerset, George F., Lonergan, Matthew, Murphy, Anne E., Smith, Julie C., Pagel, John M.
Publicado em 2010
“...We conducted a multi-center phase II trial of gemcitabine (G), carboplatin (C), dexamethasone (D...”Publicado em 2010
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
47
Por V. M. Gorbunov, E. J. Fedorova, A. D. Deev, E. V. Platonova, O. J. Isaikina
Publicado em 2016-01-01
Assuntos:
“...non-dippers...”Publicado em 2016-01-01
Obter o texto integral
Artigo
48
Por Barnes, Jeffrey A., Jacobsen, Eric, Feng, Yang, Freedman, Arnold, Hochberg, Ephraim P., LaCasce, Ann S., Armand, Philippe, Joyce, Robin, Sohani, Aliyah R., Rodig, Scott J., Neuberg, Donna, Fisher, David C., Abramson, Jeremy S.
Publicado em 2013
“...Diffuse large B-cell lymphoma is an aggressive non-Hodgkin's lymphoma without a standard therapy...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
49
Por Conroy, T, Hebbar, M, Bennouna, J, Ducreux, M, Ychou, M, Llédo, G, Adenis, A, Faroux, R, Rebischung, C, Kockler, L, Douillard, J Y
Publicado em 2010
“...BACKGROUND: A phase-III trial showed the non-inferiority of oral capecitabine plus oxaliplatin...”Publicado em 2010
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
50
Por Johnson, Matthew L., Emhoff, Chi-An W., Horning, Michael A., Brooks, George A.
Publicado em 2012
“.... Under all conditions studied, control 1.2 (SD 0.7) (Con), LC 1.9 (SD 2.5), and Epi 1.9 (SD 3.5) mg/min...”Publicado em 2012
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
51
Por WONG, NAN SOON, FERNANDO, NISHAN H., NIXON, ANDREW B., CUSHMAN, STEPHANIE, AKLILU, MEBEA, BENDELL, JOHANNA C., MORSE, MICHAEL A., BLOBE, GERARD C., ASHTON, JILL, PANG, HERBERT, HURWITZ, HERBERT I.
Publicado em 2011
“... 130 mg/m(2) and bevacizumab 7.5 mg/kg every three weeks, capecitabine 850 mg/m(2) twice daily on days...”Publicado em 2011
Obter o texto integral
Obter o texto integral
Artigo
52
Por Hida, Naoya, Okamoto, Hiroaki, Misumi, Yuuki, Sato, Akira, Ishii, Mari, Kashizaki, Fumihiro, Shimokawa, Tsuneo, Shimizu, Teppei, Watanabe, Koshiro
Publicado em 2012
“... (60 Gy in 30 fractions) once daily starting on day 2. Concurrent P (day 1; 60 mg/m(2) at Levels 1–3...”Publicado em 2012
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
53
Por Lovera, Jesus, Ramos, Alexander, Devier, Deidre, Garrison, Virginia, Kovner, Blake, Reza, Tara, Koop, Dennis, Rooney, William, Foundas, Anne, Bourdette, Dennis
Publicado no J Neurol Sci (2015)
“... capsules from a new lot (L0206306). Both lots had similar levels of EGCG but differed in the levels...”Publicado no J Neurol Sci (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
54
“... of the spine and sacroiliac joints was performed with a 1.5 T scanner at baseline and at 3 months to determine...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
55
“... and 0.22, respectively. CONCLUSIONS: A multimodal non-drug therapy of dementia resulted in stabilisation...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
56
Por Kirschbaum, Mark H., Foon, Kenneth A., Frankel, Paul, Ruel, Christopher, Pulone, Bernadette, Tuscano, Joseph M., Newman, Edward M.
Publicado em 2014
“... dose of 1000 mg/m2 daily on days 1–5 of a 21-day cycle until progression or unacceptable toxicity...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
57
Por Neal, Joel W., Dahlberg, Suzanne E., Wakelee, Heather A., Aisner, Seena C., Bowden, Michaela, Huang, Ying, Carbone, David P., Gerstner, Gregory J., Lerner, Rachel E., Rubin, Jerome L., Owonikoko, Taofeek K., Stella, Philip J., Steen, Preston D., Khalid, Ahmed Ali, Ramalingam, Suresh S.
Publicado no Lancet Oncol (2016)
“...%) to detect a PFS hazard ratio (HR) of 0.5 (1-sided p-value 0.10-level). Secondary objectives were overall...”Publicado no Lancet Oncol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
58
Por Kutlar, Abdullah, Ataga, Kenneth, Reid, Marvin, Vichinsky, Elliott P., Neumayr, Lynne, Blair-Britt, Loray, Labotka, Richard, Glass, Jonathan, Keefer, Jeffrey R., Wargin, William A., Berenson, Ronald, Perrine, Susan P.
Publicado em 2012
“... agent, was evaluated in a randomized, blinded, dose-ranging Phase I/II trial in 24 adult patients...”Publicado em 2012
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
59
Por Okamoto, Isamu, Miyazaki, Masaki, Morinaga, Ryotaro, Kaneda, Hiroyasu, Ueda, Shinya, Hasegawa, Yoshikazu, Satoh, Taroh, Kawada, Akira, Fukuoka, Masahiro, Fukino, Koichi, Tanigawa, Takahiko, Nakagawa, Kazuhiko
Publicado em 2009
Assuntos:
“...Phase I Studies...”Publicado em 2009
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
60
Por Omuro, Antonio, Beal, Kathryn, McNeill, Katharine, Young, Robert J., Thomas, Alissa, Lin, Xuling, Terziev, Robert, Kaley, Thomas J., DeAngelis, Lisa M., Daras, Mariza, Gavrilovic, Igor T., Mellinghoff, Ingo, Diamond, Eli L., McKeown, Andrew, Manne, Malbora, Caterfino, Andrew, Patel, Krishna, Bavisotto, Linda, Gorman, Greg, Lamson, Michael, Gutin, Philip, Tabar, Viviane, Chakravarty, Debyani, Chan, Timothy A., Brennan, Cameron W., Garrett-Mayer, Elizabeth, Karmali, Rashida A., Pentsova, Elena
Publicado no J Clin Oncol (2018)
“...PURPOSE: Carboxyamidotriazole orotate (CTO) is a novel oral inhibitor of non–voltage-dependent...”Publicado no J Clin Oncol (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo